Date: July 27, 2026

Financial Performance Overview

Senores Pharmaceuticals Limited reported unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), showing strong growth across key metrics.

Consolidated Financial Highlights

  • Revenue growth of 35.9% Year-over-Year (YoY)
  • EBITDA growth of 87% YoY
  • EBITDA margin expansion of approximately 800 basis points YoY

Segmental Performance

| Segment | Q1 FY27 (₹ crs) | Q1 FY26 (₹ crs) | YoY Growth |

| Regulated Markets | 127.8 | 90.1 | 41.9% |

| Emerging Markets | 37.6 | 29.0 | 29.6% |

| Branded Generics | 8.0 | 8.2 | -2.4% |

| Others | 6.8 | 5.2 | 29.2% |

| Total Revenue | 180.2 | 132.6 | 35.9% |

Operational and Business Highlights

Portfolio Expansion

  • Nearly doubled Regulated Markets portfolio from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026
  • 23 ANDAs have been commercialized

Market Performance

  • Regulated Markets: 42% YoY revenue growth driven by portfolio expansion and differentiated sales & distribution channels
  • Emerging Markets: 30% YoY revenue growth with EBITDA margin at approximately 14%
  • Emerging Markets business is now cash flow positive

Manufacturing Capacity

  • Added Baroda-based USFDA approved manufacturing plant
  • Production already ramped up at Apnar facility
  • Full scale-up and further expansion expected over next 12-18 months
  • Enhanced scalability and access to Regulated Markets
  • Enables accelerated product launches and improves operating leverage
  • Expands CDMO & CMO opportunities

Future Outlook

  • Expect strong revenue growth and expanding profitability for FY27
  • Robust product pipeline with strong visibility of commercial launches over coming quarters
  • Specific purpose marketing and distribution subsidiaries expected to scale up significantly over next few years
  • Well positioned to sustain growth momentum

Management Commentary

Mr. Swapnil Shah, Managing Director, commented on the performance:

  • Delivered healthy performance despite challenging operating environment
  • Regulated Markets growth driven by continuous expansion of product portfolio and differentiated sales channels
  • Portfolio strengthened through balanced blend of in-house development and targeted acquisitions
  • Emerging Markets shift towards niche products driving margin improvement
  • Execution-driven culture embedded across Senores
  • Confidence in sustaining momentum led by robust product pipeline, expanded manufacturing capacities, and strengthened R&D infrastructure

Company Background

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company developing and manufacturing pharmaceutical products for US, Canada, and other regulated and emerging markets.

Manufacturing Facilities

  • 3 formulation facilities: Atlanta, US (USFDA approved, DEA/BAA compliant); Gujarat, India (USFDA approved); Chhatral, Ahmedabad (WHO-GMP approved for Emerging Markets)
  • 2 API manufacturing facilities in India (Chhatral and Naroda, both around Ahmedabad)
  • 3 R&D sites (1 in USA, 2 in India)

Current Portfolio

  • 58 ANDAs and 16 CMO/CDMO commercial products permitted for distribution in USA
  • More than 40 countries served in emerging markets
  • Manufacturing facility in Chhatral approved by regulatory bodies of more than 10 countries
  • 513 product registrations and 942 product applications for emerging markets
  • Manufactures critical care injectables and Active Pharmaceutical Ingredients (API)